Online First

Neoadjuvant immune therapy also effective in MSS/pMRR CRC

Presented By

Dr Mehraneh Jafari, Weill Cornell Medical Center, NY, USA

Trial

Phase 2, NEST-1

Conference

ESMO GI 2024

Type

News article

3 July 2024 09:49

Both TAP score and CPS are viable estimates of PD-L1 expression

Presented By

Dr Eric Raymond, Hôpital Paris Saint-Joseph, France

Trial

Phase 3, RATIONALE-306

Conference

ESMO GI 2024

Type

News article

3 July 2024 09:47

Sequence effect for third-line treatment of mCRC

Presented By

Prof. Michel Ducreux, Institut Gustave Roussy, France

Trial

Phase 2, SOREGATT

Conference

ESMO GI 2024

Type

News article

3 July 2024 09:45

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By

Prof. Do-Youn Oh, Seoul National University, Korea

Trial

Phase 3, TOPAZ-1

Conference

ESMO GI 2024

Type

News article

2 July 2024 12:44

REGINA meets stage 1 endpoint and moves to stage 2 with reduced dose regorafenib

Presented By

Dr Francesco Sclafani, Institut Jules Bordet, Belgium

Trial

Phase 2, REGINA

Conference

ESMO GI 2024

Type

News article

2 July 2024 12:42

Promising first results of mitazalimab in metastatic pancreatic ductal adenocarcinoma

Presented By

Dr Teresa Macarulla, Vall d’Hebron University Hospital, Spain

Trial

Phase 1/2, OPTIMIZE-1

Conference

ESMO GI 2024

Type

News article

2 July 2024 10:37

High efficacy of pembrolizumab combined with standard therapy in patients with pMMR/MMS mCRC and high immune infiltrate

Presented By

Dr David Tougeron, Université de Poitiers, France

Trial

Phase 2, POCHI

Conference

ESMO GI 2024

Type

News article

2 July 2024 10:34

OS benefit in ARMANI, but is it worth it?

Presented By

Dr Giovanni Randon, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 3, ARMANI

Conference

ESMO GI 2024

Type

News article

1 July 2024 15:15

KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, KEYNOTE-585

Conference

ESMO GI 2024

Type

News article

1 July 2024 15:13

TRANSMET met OS endpoint

Presented By

Dr Maximiliano Gelli, Institut Gustave Roussy, France

Trial

TRANSMET

Conference

ESMO GI 2024

Type

News article

1 July 2024 15:11

Post-operative MRD status more prognostic than TNM stage

Presented By

Dr Arvind Dasari, MD Anderson Cancer Center, TX, USA

Conference

ESMO GI 2024

Type

News article

1 July 2024 10:56

177Lu-DOTATATE significantly extends PFS in patients with GEP-NETs, regardless of grade or origin

Presented By

Dr Simron Singh, University of Toronto, Canada

Trial

Phase 3, NETTER-2

Conference

ESMO GI 2024

Type

News article

1 July 2024 10:54

Peri- or post-operative chemotherapy benefits patients with resectable CRCLM

Presented By

Dr Giacomo Bregni, Hôpital Universitaire de Bruxelles, Belgium

Trial

EORTC RP-2145

Conference

ESMO GI 2024

Type

News article

1 July 2024 10:51

Lunresertib with FOLFIRI slays in MINOTAUR

Presented By

Dr Elisa Fontana, Sarah Cannon Research Institute, United Kingdom

Trial

Phase 1, MINOTAUR

Conference

ESMO GI 2024

Type

News article

28 June 2024 11:53

CAPRI 2-GOIM trial navigates biomarker-driven therapy

Presented By

Dr Giulia Martini, Università degli Studi della Campania "Luigi Vanvitelli”, Italy

Trial

Phase 2, CAPRI 2-GOIM

Conference

ESMO GI 2024

Type

News article

28 June 2024 11:50

Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for MF?

Presented By

Dr Raajit Rampal, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, MANIFEST-2

Conference

EHA 2024

Type

News article

20 June 2024 11:08

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

News article

20 June 2024 11:06

Promising results for novel CAR T-cell therapy in MM in phase 1 trial

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

News article

20 June 2024 10:59

ESLIM-01: Sovleplenib delivers durable responses and QoL improvements in primary ITP

Presented By

Dr Renchi Yang, Chinese Academy of Medical Sciences, China

Trial

Phase 3, ESLIM-01

Conference

EHA 2024

Type

News article

20 June 2024 10:58

AUGMENT-101: revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

News article

20 June 2024 10:57

Clinically meaningful outcomes for mosunetuzumab across FL subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 2

Conference

EHA 2024

Type

News article

20 June 2024 10:55

Giant cell arteritis: Upadacitinib may be an upcoming treatment option

Presented By

Prof. Daniel Blockmans, University Hospitals Leuven, Belgium

Trial

Phase 3, SELECT-GCA

Conference

EULAR 2024

Type

News article

19 June 2024 12:07

Early treatment with ambrisentan might prevent PAH development in patients with SSc

Presented By

Dr Panagiota Xanthouli, Heidelberg University Hospital, Germany

Trial

Phase 2, EDITA

Conference

EULAR 2024

Type

News article

19 June 2024 12:05

Nipocalimab meets primary endpoint in Sjögren’s disease

Presented By

Prof. Jacques-Eric Gottenberg, Strasbourg University Hospital, France

Trial

Phase 2, DAHLIAS

Conference

EULAR 2024

Type

News article

19 June 2024 12:04

Daratumumab shows promise in systemic lupus erythematosus

Presented By

Dr Tobias Alexander, Charité-University Medicine Berlin, Germany

Trial

Phase 2

Conference

EULAR 2024

Type

News article

19 June 2024 12:03

Tophaceous gout more prone to increase the mortality risk than non-tophaceous

Presented By

Dr Gregory Challener, Massachusetts General Hospital, USA

Conference

EULAR 2024

Type

News article

19 June 2024 12:01

AxSpA: Comorbidities associated with more pronounced radiographic progression

Presented By

Dr Sizheng Zhao, University of Manchester, UK

Conference

EULAR 2024

Type

News article

19 June 2024 12:00

Excellent phase 3 results for asciminib in CML

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

News article

19 June 2024 09:55

EPCORETM CLL-1: promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

News article

19 June 2024 09:54

ENERGIZE: mitapivat meets primary efficacy endpoint in thalassaemia

Presented By

Prof. Ali Taher, American University of Beirut, Lebanon

Trial

Phase 3, ENERGIZE

Conference

EHA 2024

Type

News article

19 June 2024 09:52

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

News article

19 June 2024 09:50

RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

Presented By

Dr Rabi Hanna, Cleveland Clinic, OH, USA

Trial

Phase 1/2, RUBY

Conference

EHA 2024

Type

News article

19 June 2024 09:48

Navitoclax plus ruxolitinib leads to spleen volume reductions in MF in TRANSFORM-1 trial

Presented By

Prof. Naveen Pemmaraju, MD Anderson Cancer Center, TX, USA

Trial

Phase 3, TRANSFORM-1

Conference

EHA 2024

Type

News article

19 June 2024 09:47

Dual IL-17 blocker significantly reduces spinal radiographic progression in r-axSpA

Presented By

Prof. Xenofon Baraliakos, Ruhr-University Bochum, Germany

Trial

BE MOBILE 2

Conference

EULAR 2024

Type

News article

18 June 2024 11:55

Small protein targeting IL-17A effective in PsA

Presented By

Prof. Philip Mease, University of Washington, USA

Trial

Phase 3

Conference

EULAR 2024

Type

News article

18 June 2024 11:53

Anti-Ro/SSA antibodies in systemic sclerosis: a novel predictor of severe lung involvement

Presented By

Dr Blaž Burja, University Hospital Zurich, Switzerland

Trial

EUSTAR

Conference

EULAR 2024

Type

News article

18 June 2024 11:51

Key predictors of rheumatoid arthritis flares identified

Presented By

Dr Fiona Rayner, Newcastle University, UK

Trial

BIO-FLARE

Conference

EULAR 2024

Type

News article

18 June 2024 11:49

Real-world comparative effectiveness of advanced therapies in psoriatic arthritis

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

PRO-SPIRIT

Conference

EULAR 2024

Type

News article

18 June 2024 11:47

More patients hit their uric acid target with febuxostat and ruzinurad combination

Presented By

Dr Huihua Ding, Shanghai Jiao Tong University, China

Trial

Phase 2

Conference

EULAR 2024

Type

News article

18 June 2024 11:44

DREAMM 8: belantamab mafodotin offers hope for patients with RR MM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

News article

18 June 2024 10:35

High survival rates following atezolizumab consolidation therapy in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

News article

18 June 2024 10:33

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Dr Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, APOLLO

Conference

EHA 2024

Type

News article

18 June 2024 10:32

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

News article

18 June 2024 10:30

Can golcadomide plus R-CHOP become the first-line standard of care in DLBCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

News article

18 June 2024 10:29

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

News article

18 June 2024 10:26

New JAK1 inhibitor outperformed placebo in active rheumatoid arthritis

Presented By

Dr Jinjing Liu, Peking Union Medical College Hospital, China

Trial

Phase 3

Conference

EULAR 2024

Type

News article

17 June 2024 11:43

Digital health app improves mental aspects of quality-of-life for patients with RA

Presented By

Prof. Frank Behrens, Goethe-University & Fraunhofer ITMP, Germany

Conference

EULAR 2024

Type

News article

17 June 2024 11:41

Greater fracture risk reduction with denosumab than bisphosphonates in osteoporosis

Presented By

Prof. Jeffrey Curtis, University of Alabama at Birmingham, USA

Conference

EULAR 2024

Type

News article

17 June 2024 11:39

Is JAK inhibition the right choice for patients with relapsing giant cell arteritis?

Presented By

Dr Fernando López Gutiérrez, University Hospital Marqués de Valdecilla, Spain

Conference

EULAR 2024

Type

News article

17 June 2024 11:38

Analysis of synovial tissue macrophages: A way to predict RA treatment response?

Presented By

Dr Simone Perniola, Policlinico Universitario A. Gemelli IRCS, Italy

Conference

EULAR 2024

Type

News article

17 June 2024 11:37

Low IL-18 levels: a risk factor for long COVID in patients with systemic autoimmune rheumatic diseases

Presented By

Dr Jeffrey Sparks, Brigham and Women's Hospital, USA

Trial

RheumCARD

Conference

EULAR 2024

Type

News article

17 June 2024 11:33